
Lilly's Foundayo Pill Reduced Sleep Apnea Severity in Two Phase 3 Trials, With an FDA Filing Planned by Year-End
Notas del episodio
Eli Lilly's once-daily GLP-1 pill Foundayo (orforglipron) reduced the severity of obstructive sleep apnea in its Phase 3 ATTAIN-OSA program, presented at the American Heart Association's Scientific Sessions 2026 and published in JAMA on November 9, 2026. The program included two 52-week, placebo-controlled trials in 712 adults with moderate-to-severe sleep apnea and overweight or obesity, without diabetes: 363 people not using positive airway pressure (PAP/CPAP) therapy and 349 who were using it. In the JAMA paper's primary analysis, breathing interruptions (the apnea-hypopnea index) fell by 17.8 events per hour with orforglipron versus 4.5 with placebo in people not using PAP, and by 17.3 versus 5.3 in people using PAP. Lilly's efficacy-estimand figures show a 43.8% and 27.5% reduction, with 31.5% and 19.6% reaching remission or mild disease, plus about 11% weight loss and lower oxygen-drop burden, inflammation and blood pressure. Gastrointestinal side effects were most common, and more people stopped treatment because of side effects on orforglipron. Foundayo is approved in the US for weight management only, not for sleep apnea; Lilly plans to submit it to the FDA for sleep apnea by the end of 2026. Zepbound is the Lilly drug already approved for moderate-to-severe sleep apnea in adults with obesity. The trials lasted one year, excluded people with diabetes, and were funded by Lilly.
Sources
- Eli Lilly and Company press release (Nov 9, 2026), Foundayo (orforglipron) ATTAIN-OSA results: investor.lilly.com
- JAMA (Nov 9, 2026), Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA): jamanetwork.com
- American Heart Association news release (Nov 9, 2026), Daily, oral GLP-1 medication reduced episodes of sleep apnea in adults with excess weight: newsroom.heart.org
- ClinicalTrials.gov, NCT06649045 (ATTAIN-OSA): clinicaltrials.gov
- Fierce Pharma (Nov 9, 2026), Lilly looks to gird Foundayo label after late-stage win in sleep apnea: fiercepharma.com
Cover: original code-generated illustration (no photo).
This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Visit glp1newspaper.com for today's stories and free email alerts.
Todos los episodios de GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News